This document is an excerpt from the EUR-Lex website
Document E2014G1009(02)
Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2012
Ravimid – EMP EFTA riikide poolt 2012. aasta esimesel poolaastal antud müügilubade nimekiri
Ravimid – EMP EFTA riikide poolt 2012. aasta esimesel poolaastal antud müügilubade nimekiri
ELT C 356, 9.10.2014, p. 22–36
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
9.10.2014 |
ET |
Euroopa Liidu Teataja |
C 356/22 |
Ravimid – EMP EFTA riikide poolt 2012. aasta esimesel poolaastal antud müügilubade nimekiri
2014/C 356/07
Kaupade vaba liikumise I allkomitee
Teadmiseks EMP ühiskomiteele
Vastavalt EMP ühiskomitee 28. mai 1999. aasta otsusele nr 74/1999 kutsutakse EMP ühiskomiteed 15. juulil 2013 toimuval koosolekul arvesse võtma järgmisi ajavahemikus 1. jaanuarist – 30. juunini 2012 antud ravimite müügilubade nimekirju:
I lisa |
Uute müügilubade nimekiri |
II lisa |
Uuendatud müügilubade nimekiri |
III lisa |
Pikendatud müügilubade nimekiri |
IV lisa |
Äravõetud müügilubade nimekiri |
V lisa |
Peatatud müügilubade nimekiri |
I LISA
Uute müügilubade nimekiri
Ajavahemikus 1. jaanuarist – 30. juunini 2012 anti EMP EFTA riikides välja järgmised müügiload:
ELi number |
Toode |
Riik |
Loa andmise kuupäev |
EU/1/11/711/001–030 |
Matever |
Norra |
1.6.2012 |
EU/1/11/712/001–028 |
Levetiracetam Accord |
Norra |
13.4.2012 |
EU/1/11/713/001–040 |
Levetiracetam Actavis |
Norra |
16.4.2012 |
EU/1/11/715/001–002 |
Plenadren |
Island |
23.4.2012 |
EU/1/11/721/001–021 |
Paglitaz |
Norra |
13.4.2012 |
EU/1/11/721/001–021 |
Paglitaz |
Island |
17.4.2012 |
EU/1/11/722/001–030 |
Pioglitazone Accord |
Norra |
11.4.2012 |
EU/1/11/722/001–030 |
Pioglitazon Accord |
Liechtenstein |
30.4.2012 |
EU/1/11/722/001–030 |
Pioglitazone Accord |
Island |
20.4.2012 |
EU/1/11/723/001–021 |
Pioglitazone Krka |
Norra |
23.5.2012 |
EU/1/11/723/001–021 |
Pioglitazone Krka |
Island |
20.4.2012 |
EU/1/11/727/001 |
Mercatopurine Nova lab. |
Norra |
19.4.2012 |
EU/1/11/727/001 |
Mercaptopurine Nova Laboratories |
Island |
3.4.2012 |
EU/1/11/727/001 |
Mercatopurine Nova Laboratories |
Liechtenstein |
30.4.2012 |
EU/1/11/729/001–006 |
Onduarp |
Norra |
8.5.2012 |
EU/1/11/730/001–060 |
Rasitrio |
Island |
3.2.2012 |
EU/1/11/738/001–003 |
Levetiracetam Actavis Gr. |
Norra |
1.3.2012 |
EU/1/11/739/001–008 |
Dasselta |
Norra |
16.1.2012 |
EU/1/11/740/001 |
Ameluz |
Island |
5.1.2012 |
EU/1/11/740/001 |
Ameluz |
Norra |
16.1.2012 |
EU/1/11/741/001 |
Levetiracetam SUN |
Norra |
27.1.2012 |
EU/1/11/741/001 |
Levetiracetam Sun |
Island |
9.1.2012 |
EU/1/11/742/001–010 |
Efavirenz Teva |
Norra |
13.2.2012 |
EU/1/11/742/001–010 |
Efavirenz Teva |
Island |
24.1.2012 |
EU/1/11/742/001–010 |
Efavirenz Teva |
Liechtenstein |
29.2.2012 |
EU/1/11/743/001–015 |
Repaglinide Accord |
Norra |
13.2.2012 |
EU/1/11/743/001–015 |
Repaglinide Accord |
Island |
19.1.2012 |
EU/1/11/743/001–015 |
Repaglinide Accord |
Liechtenstein |
29.2.2012 |
EU/1/11/744/001–002 |
Topotecan Eagle |
Island |
22.1.2012 |
EU/1/11/744/001–002 |
Topotecan Eagle |
Liechtenstein |
29.2.2012 |
EU/1/11/745/001–009 |
Desloratadine Actavis |
Island |
3.2.2012 |
EU/1/11/745/001–009 |
Desloratadine Actavis |
Norra |
13.2.2012 |
EU/1/11/746/001–012 |
Desloratadine ratiopharm |
Norra |
13.2.2012 |
EU/1/11/746/001–012 |
Desloratadine ratiopharm |
Island |
3.2.2012 |
EU/1/11/746/001–012 |
Desloratadine ratiopharm |
Liechtenstein |
29.2.2012 |
EU/1/11/747/001 |
Colobreathe |
Island |
29.2.2012 |
EU/1/11/747/001 |
Colobreathe |
Liechtenstein |
29.2.2012 |
EU/1/11/748/001–006 |
Docetaxel Mylan |
Island |
7.2.2012 |
EU/1/11/748/001–006 |
Docetaxel Mylan |
Liechtenstein |
29.2.2012 |
EU/1/11/749/001–002 |
Caprelsa |
Liechtenstein |
30.4.2012 |
EU/1/11/749/001–003 |
Caprelsa |
Island |
9.3.2012 |
EU/1/11/749/001–002 |
Caprelsa |
Norra |
13.3.2012 |
EU/1/12/750/001 |
Esmya |
Norra |
30.3.2012 |
EU/1/12/750/001 |
Esmya |
Island |
14.3.2012 |
EU/1/12/750/001 |
Esmya |
Liechtenstein |
30.4.2012 |
EU/1/12/751/001 |
Zelboraf |
Norra |
14.3.2012 |
EU/1/12/751/001 |
Zelboraf |
Island |
7.3.2012 |
EU/1/12/751/001 |
Zelboraf |
Liechtenstein |
29.2.2012 |
EU/1/12/752/001 |
Vepacel |
Norra |
1.3.2012 |
EU/1/12/752/001 |
Vepacel |
Island |
9.3.2012 |
EU/1/12/752/001 |
Vepacel |
Liechtenstein |
29.2.2012 |
EU/1/12/753/001–012 |
Signifor |
Norra |
10.5.2012 |
EU/1/12/753/001–012 |
Signifor |
Island |
24.5.2012 |
EU/1/12/753/001–012 |
Signifor |
Liechtenstein |
30.6.2012 |
EU/1/12/754/001–021 |
Sepioglin |
Norra |
10.4.2012 |
EU/1/12/754/001–021 |
Sepioglin |
Island |
3.4.2012 |
EU/1/12/754/001–021 |
Sepioglin |
Liechtenstein |
30.4.2012 |
EU/1/12/755/001–027 |
Pioglitazone Actavis |
Norra |
13.4.2012 |
EU/1/12/755/001–027 |
Pioglitazone Actavis |
Island |
30.4.2012 |
EU/1/12/756/001–027 |
Glidipion (ex Ogliton) |
Norra |
13.4.2012 |
EU/1/12/756/001–027 |
Pioglitazone Actavis Group |
Island |
13.4.2012 |
EU/1/12/756/001–027 |
Pioglitazone Actavis Group |
Liechtenstein |
30.4.2012 |
EU/1/12/757/001–030 |
Pioglitazone Teva |
Norra |
11.4.2012 |
EU/1/12/757/001–030 |
Pioglitazone Teva |
Island |
23.4.2012 |
EU/1/12/758/001–030 |
Pioglitazone Teva Pharma |
Norra |
17.4.2012 |
EU/1/12/758/001–030 |
Pioglitazone Teva Pharma |
Island |
25.4.2012 |
EU/1/12/759/001–003 |
Zoledronic acid Actavis |
Norra |
8.5.2012 |
EU/1/12/759/001–003 |
Zoledronic acid Actavis |
Island |
16.5.2012 |
EU/1/12/759/001–003 |
Zoledronsäure Actavis |
Liechtenstein |
30.4.2012 |
EU/1/12/760/001–002 |
Bronchitol |
Norra |
18.5.2012 |
EU/1/12/760/001–002 |
Bronchitol |
Island |
9.5.2012 |
EU/1/12/761/001–002 |
Capecitabine Teva |
Norra |
30.5.2012 |
EU/1/12/761/001–002 |
Capecitabine Teva |
Island |
20.5.2012 |
EU/1/12/761/001–002 |
Capecitabin Teva |
Liechtenstein |
30.4.2012 |
EU/1/12/762/001–018 |
Capecitabine Accord |
Island |
20.5.2012 |
EU/1/12/762/001–018 |
Capecitabin Accord |
Liechtenstein |
30.4.2012 |
EU/1/12/763/001–018 |
Capecitabine Krka |
Island |
16.5.2012 |
EU/1/12/763/001–018 |
Capecitabin Krka |
Liechtenstein |
30.4.2012 |
EU/1/12/763/001–018 |
Capecitabine Krka |
Norra |
14.6.2012 |
EU/1/12/764/001 |
Pixuvri |
Norra |
14.6.2012 |
EU/1/12/764/001 |
Pixuvri |
Island |
29.5.2012 |
EU/1/12/764/001 |
Pixuvri |
Liechtenstein |
30.6.2012 |
EU/1/12/765/001–004 |
Sabervel |
Island |
9.5.2012 |
EU/1/12/765/001–006 |
Sabervel |
Norra |
8.5.2012 |
EU/1/12/765/001–006 |
Sabervel |
Liechtenstein |
30.4.2012 |
EU/1/12/766/001 |
Sancuso |
Norra |
10.5.2012 |
EU/1/12/766/001 |
Sancuso |
Island |
20.5.2012 |
EU/1/12/766/001 |
Sancuso |
Liechtenstein |
30.6.2012 |
EU/1/12/767/001–007 |
Nimenrix |
Norra |
1.5.2012 |
EU/1/12/767/001–007 |
Nimenrix |
Island |
16.5.2012 |
EU/1/12/768/001 |
Riluzole Zentiva |
Island |
25.5.2012 |
EU/1/12/768/001 |
Riluzol Zentiva |
Liechtenstein |
30.6.2012 |
EU/1/12/769/001–003 |
Docetaxel Accord |
Island |
12.6.2012 |
EU/1/12/769/001–003 |
Docetaxel Accord |
Liechtenstein |
30.6.2012 |
EU/1/12/770/001–004 |
Docetaxel Kabi |
Norra |
19.6.2012 |
EU/1/12/770/001–004 |
Docetaxel Kabi |
Island |
13.6.2012 |
EU/1/12/770/001–004 |
Docetaxel Kabi |
Liechtenstein |
30.6.2012 |
EU/2/11/134/001–014 |
Inflacam |
Norra |
6.1.2012 |
EU/2/11/135/001–003 |
Panacur AquaSol |
Norra |
10.2.2012 |
EU/2/11/136/001 |
Truscient |
Norra |
6.1.2012 |
EU/2/11/136/001 |
TruScient |
Island |
12.1.2012 |
EU/2/11/137/001–015 |
Activyl Tick Plus |
Norra |
13.2.2012 |
EU/2/11/137/001–015 |
Activyl Tick Plus |
Island |
25.1.2012 |
EU/2/11/137/001–015 |
Activyl Tick Plus |
Liechtenstein |
29.2.2012 |
EU/2/12/138/001–003 |
RevitaCAM |
Island |
14.3.2012 |
EU/2/12/139/001–003 |
Zulvac 1 + 8 Bovis |
Norra |
3.4.2012 |
EU/2/12/139/001–003 |
Zulvac 1 + 8 Bovis |
Island |
4.4.2012 |
EU/2/12/139/001–003 |
Zulvac 1 + 8 Bovis |
Liechtenstein |
30.4.2012 |
II LISA
Uuendatud müügilubade nimekiri
Ajavahemikus 1. jaanuarist – 30. juunini 2012 anti EMP EFTA riikides välja järgmised müügiload:
ELi number |
Toode |
Riik |
Loa andmise kuupäev |
EU/1/01/197/001–005 |
Foscan |
Island |
14.5.2012 |
EU/1/01/200/001–002 |
Viread |
Norra |
6.1.2012 |
EU/1/01/200/001–002 |
Viread |
Island |
5.1.2012 |
EU/1/02/209/001–008 |
Dynastat |
Norra |
8.3.2012 |
EU/1/02/209/001–008 |
Dynastat |
Island |
7.2.2012 |
EU/1/02/209/001–008 |
Dynastat |
Liechtenstein |
29.2.2012 |
EU/1/02/212/001–026 |
Vfend |
Norra |
6.3.2012 |
EU/1/02/212/001–026 |
Vfend |
Island |
14.3.2012 |
EU/1/02/212/001–026 |
Vfend |
Liechtenstein |
30.4.2012 |
EU/1/02/216/001–002 |
Invanz |
Norra |
19.1.2012 |
EU/1/02/216/001–002 |
Invanz |
Island |
20.1.2012 |
EU/1/02/216/001–002 |
Invanz |
Liechtenstein |
29.2.2012 |
EU/1/02/220/001–006 |
Tracleer |
Norra |
8.5.2012 |
EU/1/02/220/001–006 |
Tracleer |
Island |
20.5.2012 |
EU/1/02/220/001–006 |
Tracleer |
Liechtenstein |
30.4.2012 |
EU/1/02/222/001–005 |
Tamiflu |
Norra |
8.3.2012 |
EU/1/02/222/001–005 |
Tamiflu |
Island |
19.6.2012 |
EU/1/02/222/001–005 |
Tamiflu |
Liechtenstein |
30.6.2012 |
EU/1/06/334/001–005 |
Evoltra |
Liechtenstein |
30.4.2012 |
EU/1/06/347/001–008 |
Sutent |
Liechtenstein |
29.2.2012 |
EU/1/06/366/005–022 |
Tandemact |
Norra |
11.4.2012 |
EU/1/06/366/005–022 |
Tandemact |
Island |
22.3.2012 |
EU/1/06/366/005–022 |
Tandemact |
Liechtenstein |
30.4.2012 |
EU/1/06/367/001–012 |
Diacomit |
Norra |
6.3.2012 |
EU/1/06/367/001–012 |
Diacomit |
Island |
7.2.2012 |
EU/1/06/367/001–012 |
Diacomit |
Liechtenstein |
29.2.2012 |
EU/1/06/370/001–039 |
Exforge |
Norra |
16.1.2012 |
EU/1/06/370/001–039 |
EXFORGE |
Island |
3.2.2012 |
EU/1/06/371/001–039 |
Dafiro |
Island |
8.2.2012 |
EU/1/06/371/001–039 |
Dafiro |
Liechtenstein |
29.2.2012 |
EU/1/06/372/001–039 |
Copalia |
Norra |
11.1.2012 |
EU/1/06/373/001–039 |
Imprida |
Norra |
16.1.2012 |
EU/1/06/373/001–039 |
Imprida |
Island |
6.2.2012 |
EU/1/06/374/001 |
Lucentis |
Norra |
17.1.2012 |
EU/1/06/374/001 |
Lucentis |
Island |
12.1.2012 |
EU/1/06/376/001–033 |
Irbesartan Zentiva (ex-Winthrop) |
Norra |
14.2.2012 |
EU/1/06/376/001–033 |
Irbesartan Zentiva |
Island |
7.2.2012 |
EU/1/06/376/001–033 |
Irbesartan Winthrop |
Liechtenstein |
29.2.2012 |
EU/1/06/377/001–028 |
Irbesartan HCT Zentiva (ex-Winthrop) |
Norra |
16.4.2012 |
EU/1/06/377/001–028 |
Irbesartan HCT Zentiva |
Island |
22.3.2012 |
EU/1/06/377/001–028 |
Irbesartan HCT |
Liechtenstein |
30.4.2012 |
EU/1/06/378/001–017 |
Inovelon |
Norra |
6.3.2012 |
EU/1/06/378/001–017 |
Inovelon |
Island |
24.1.2012 |
EU/1/06/378/001–017 |
Inovelon |
Liechtenstein |
29.2.2012 |
EU/1/06/379/001 |
Cystadane |
Island |
9.3.2012 |
EU/1/06/379/001 |
Cystadane |
Liechtenstein |
29.2.2012 |
EU/1/06/386/001–015, 020–024, 029–033, 038–042, 047–051, 056–057, 088102, 113–150, 163–168 |
Insulin Human Winthrop |
Norra |
6.1.2012 |
EU/1/07/382/001–018 |
Xelevia |
Norra |
14.2.2012 |
EU/1/07/382/001–018 |
Xelevia |
Island |
6.2.2012 |
EU/1/07/382/001–018 |
Xelevia |
Liechtenstein |
29.2.2012 |
EU/1/07/383/001–018 |
Januvia |
Norra |
26.3.2012 |
EU/1/07/383/001–018 |
Januvia |
Island |
11.5.2012 |
EU/1/07/383/001–018 |
Januvia |
Liechtenstein |
30.4.2012 |
EU/1/07/384/003–005 |
Docetaxel Winthrop |
Norra |
10.4.2012 |
EU/1/07/384/003–005 |
Docetaxel Winthrop |
Island |
23.3.2012 |
EU/1/07/384/003–005 |
Docetaxel Winthrop |
Liechtenstein |
30.4.2012 |
EU/1/07/386/001–018 |
Toviaz |
Norra |
11.4.2012 |
EU/1/07/386/001–018 |
Toviaz |
Island |
10.4.2012 |
EU/1/07/386/001–018 |
Toviaz |
Liechtenstein |
30.4.2012 |
EU/1/07/387/001–026 |
Advagraf |
Norra |
2.5.2012 |
EU/1/07/387/001–026 |
Advagraf |
Island |
9.5.2012 |
EU/1/07/387/001–026 |
Advagraf |
Liechtenstein |
30.4.2012 |
EU/1/07/388/001–003 |
Sebivo |
Norra |
8.5.2012 |
EU/1/07/388/001–003 |
Sebivo |
Island |
16.5.2012 |
EU/1/07/388/001–003 |
Sebivo |
Liechtenstein |
30.4.2012 |
EU/1/07/389/001–003 |
Orencia |
Norra |
10.4.2012 |
EU/1/07/389/001–003 |
Orencia |
Island |
10.4.2012 |
EU/1/07/389/001–003 |
Orencia |
Liechtenstein |
30.4.2012 |
EU/1/07/390/001–004 |
Altargo |
Norra |
8.5.2012 |
EU/1/07/390/001–004 |
Altargo |
Island |
16.5.2012 |
EU/1/07/390/001–004 |
Altargo |
Liechtenstein |
30.4.2012 |
EU/1/07/391/001–004 |
Revlimid |
Norra |
3.5.2012 |
EU/1/07/391/001–004 |
Revlimid |
Island |
9.5.2012 |
EU/1/07/391/001–004 |
Revlimid |
Liechtenstein |
30.4.2012 |
EU/1/07/392/001–003 |
Circadin |
Norra |
16.5.2012 |
EU/1/07/392/001–003 |
Circadin |
Island |
10.5.2012 |
EU/1/07/392/001–003 |
Circadin |
Liechtenstein |
30.6.2012 |
EU/1/07/394/001–009 |
Optaflu |
Norra |
20.6.2012 |
EU/1/07/395/001–095 |
Invega |
Liechtenstein |
30.6.2012 |
EU/1/07/396/001–003 |
Pergoveris |
Island |
20.6.2012 |
EU/1/07/396/001–003 |
Pergoveris |
Liechtenstein |
30.6.2012 |
EU/1/07/398/001–014 |
Optimark |
Norra |
27.6.2012 |
EU/1/07/399/001–006 |
Aerinaze |
Norra |
18.6.2012 |
EU/1/07/399/001–006 |
Aerinaze |
Liechtenstein |
30.6.2012 |
EU/1/07/399/001–006 |
Aerinaze |
Island |
20.6.2012 |
EU/1/07/400/008–013, 017–024 |
Mircera |
Island |
7.6.2012 |
EU/1/07/400/008–013, 017–024 |
Mircera |
Norra |
14.6.2012 |
EU/1/07/400/017–024 |
Mircera |
Liechtenstein |
30.6.2012 |
EU/1/07/401/007–016 |
alli |
Norra |
29.6.2012 |
EU/1/07/412/001–052 |
Abseamed |
Liechtenstein |
30.6.2012 |
EU/1/07/423/001–003 |
Vectibix |
Norra |
19.3.2012 |
EU/1/07/423/001–003 |
Vectibix |
Island |
9.3.2012 |
EU/1/07/440/001–003 |
Tyverb |
Liechtenstein |
30.4.2012 |
EU/1/07/440/001–006 |
Tyverb |
Norra |
2.5.2012 |
EU/1/07/440/001–006 |
Tyverb |
Island |
11.5.2012 |
EU/1/10/625/001&003 |
Arzerra |
Island |
17.2.2012 |
EU/1/10/625/001&003 |
Arzerra |
Norra |
18.5.2012 |
EU/1/10/628/001–004 |
Votrient |
Norra |
19.6.2012 |
EU/1/10/628/001–004 |
Votrient |
Island |
13.6.2012 |
EU/1/11/699/001–004 |
Fampyra |
Norra |
19.6.2012 |
EU/1/11/699/001–004 |
Fampyra |
Island |
13.6.2012 |
EU/1/11/699/001–004 |
Fampyra |
Liechtenstein |
30.6.2012 |
EU/2/05/053/001–003 |
Naxcel |
Norra |
14.2.2012 |
EU/2/06/068/001–004 |
Ypozane |
Norra |
13.2.2012 |
EU/2/06/068/001–004 |
Ypozane |
Island |
18.1.2012 |
EU/2/06/068/001–004 |
Ypozane |
Liechtenstein |
30.4.2012 |
EU/2/06/070/001–008 |
Meloxidyl |
Island |
13.1.2012 |
EU/2/07/071/001–003 |
SLENTROL |
Island |
7.5.2012 |
EU/2/07/071/001–003 |
Slentrol |
Liechtenstein |
30.4.2012 |
EU/2/07/072/001–004 |
Suprelorin |
Island |
21.6.2012 |
EU/2/07/074/001–006 |
Prilactone |
Island |
13.6.2012 |
EU/2/07/075/001–004 |
Circovac |
Liechtenstein |
30.6.2012 |
EU/2/07/075/001–004 |
Circovac |
Island |
4.6.2012 |
III LISA
Pikendatud müügilubade nimekiri
Ajavahemikus 1. jaanuarist – 30. juunini 2012 pikendati EMP EFTA riikides järgmised müügiload:
ELi number |
Toode |
Riik |
Loa andmise kuupäev |
EU/1/00/141/002 |
Myocet |
Liechtenstein |
30.4.2012 |
EU/1/02/222/05 |
Tamiflu |
Island |
6.2.2012 |
EU/1/03/262/009–010 |
Emend |
Norrra |
5.1.2012 |
EU/1/03/262/009–010 |
Emend |
Island |
3.2.2012 |
EU/1/03/271/007–010 |
Advate |
Norra |
23.1.2012 |
EU/1/03/271/007–010 |
Advate |
Island |
17.1.2012 |
EU/1/05/318/003 |
Revatio |
Norra |
13.4.2012 |
EU/1/05/318/003 |
Revatio |
Island |
17.4.2012 |
EU/1/05/318/003 |
Revatio |
Liechtenstein |
30.4.2012 |
EU/1/06/339/003 |
Preotact |
Liechtenstein |
30.6.2012 |
EU/1/08/465/021 |
Clopidogrel Zentiva |
Liechtenstein |
30.6.2012 |
EU/1/08/468/002 |
INTELENCE |
Island |
3.1.2012 |
EU/1/08/470/018–019 |
Vimpat |
Norra |
14.3.2012 |
EU/1/08/470/018–019 |
Vimpat |
Island |
14.3.2012 |
EU/1/08/470/018–019 |
Vimpat |
Liechtenstein |
30.4.2012 |
EU/1/08/472/011–021 |
Xarelto |
Norra |
4.1.2012 |
EU/1/08/475/035–060 |
Olanzapin Mylan |
Liechtenstein |
29.2.2012 |
EU/1/09/536/003–004 |
Topotecan Actavis |
Liechtenstein |
30.4.2012 |
EU/1/09/551/013–027 |
Vizarsin |
Island |
7.6.2012 |
EU/1/09/551/013–027 |
Vizarsin |
Liechtenstein |
30.6.2012 |
EU/1/09/571/002 |
Pandemic influenza vaccine H5N1 Baxter |
Liechtenstein |
30.4.2012 |
EU/1/11/667/004 |
Esbriet |
Liechtenstein |
30.4.2012 |
EU/1/11/699/003–004 |
Fampyra |
Liechtenstein |
30.4.2012 |
EU/1/11/701/029–032 |
Levetiracetam Teva |
Liechtenstein |
30.6.2012 |
EU/1/11/703/003 |
Xgeva |
Liechtenstein |
29.2.2012 |
EU/1/11/704/002 |
Victrelis |
Liechtenstein |
30.4.2012 |
EU/1/11/720/002 |
Incivo |
Liechtenstein |
30.6.2012 |
EU/1/97/044/009 |
Tasmar |
Liechtenstein |
30.4.2012 |
EU/2/07/078/015–017 |
Rheumocam |
Norra |
13.2.2012 |
EU/2/07/078/015–017 |
Rheumocam |
Island |
7.2.2012 |
EU/2/07/078/015–017 |
Rheumocam |
Liechtenstein |
29.2.2012 |
EU/2/08/085/002–006 |
Easotic |
Liechtenstein |
30.4.2012 |
EU/2/08/090/027 |
Loxicom |
Liechtenstein |
30.6.2012 |
EU/2/10/114/003 |
Hiprabovis IBR Marker Live |
Liechtenstein |
29.2.2012 |
EU/2/97/004/049 |
Metacam |
Liechtenstein |
29.2.2012 |
IV LISA
Äravõetud müügilubade nimekiri
Ajavahemikus 1. jaanuarist – 30. juunini 2012 võeti EMP EFTA riikides ära järgmised müügiload:
ELi number |
Toode |
Riik |
Tagasivõtmise kuupäev |
EU/1/02/255/001–002 |
Xigris |
Island |
25.6.2012 |
EU/1/04/272/001–002 |
PhotoBarr |
Norra |
24.5.2012 |
EU/1/04/272/001–002 |
Photobarr |
Island |
20.5.2012 |
EU/1/04/272/001–002 |
PhotoBarr |
Liechtenstein |
30.6.2012 |
EU/1/06/335/001 |
Valtropin |
Island |
5.6.2012 |
EU/1/06/335/001 |
Valtropin |
Liechtenstein |
30.6.2012 |
EU/1/06/351/001–003 |
Livensa |
Island |
11.4.2012 |
EU/1/06/351/001–003 |
Livensa |
Liechtenstein |
30.4.2012 |
EU/1/06/352/001–003 |
Intrinsa |
Liechtenstein |
30.6.2012 |
EU/1/06/352/001–003 |
Intrinsa |
Island |
23.6.2012 |
EU/1/09/534/001–007 |
Clopidogrel Hexal |
Island |
2.3.2012 |
EU/1/09/534/001–007 |
Clopidgrel Hexal |
Liechtenstein |
29.2.2012 |
EU/1/09/548/001–007 |
Clopidogrel Acino Pharma GmbH |
Island |
2.3.2012 |
EU/1/09/548/001–007 |
Clopidgrel Acino Pharma GmbH |
Liechtenstein |
29.2.2012 |
EU/1/09/549/001–007 |
Clopidogrel Acino Pharma |
Island |
2.3.2012 |
EU/1/09/549/001–007 |
Clopidogrel Acino Pharma |
Liechtenstein |
29.2.2012 |
EU/1/10/630/001–002 |
Docefrez |
Island |
20.6.2012 |
EU/1/10/630/001–002 |
Docefrez |
Liechtenstein |
30.6.2012 |
EU/1/97/035/003–004 |
Refludan |
Island |
24.5.2012 |
EU/1/97/035/001–004 |
Refludan |
Norra |
6.6.2012 |
EU/1/97/035/001–004 |
Refludan |
Liechtenstein |
30.6.2012 |
EU/2/00/028/002–008 |
Zubrin |
Island |
17.4.2012 |
EU/2/00/028/002–008 |
Zubrin |
Liechtenstein |
30.4.2012 |
EU/2/03/040/001–002 |
Gonazon |
Norra |
2.4.2012 |
EU/2/03/040/001–002 |
Gonazon |
Island |
17.4.2012 |
EU/2/03/040/001–002 |
Gonazon |
Liechtenstein |
30.4.2012 |
EU/2/06/060/001–002 |
Poulvac FluFend H5N3 RG |
Liechtenstein |
30.6.2012 |
V LISA
Peatatud müügilubade nimekiri
Ajavahemikus 1. jaanuarist – 30. juunini 2012 peatati EMP EFTA riikides järgmised müügiload:
ELi number |
Toode |
Riik |
Peatamise kuupäev |
EU/1/06/361/001–002 |
Luminity |
Island |
20.6.2012 |
EU/1/06/361/001–002 |
Luminity |
Liechtenstein |
30.6.2012 |
EU/1/97/037/001 |
Vistide |
Liechtenstein |
29.2.2012 |
EU/1/11/705/001 |
Vibativ |
Island |
27.6.2012 |